Addiction & Substance Use Treatment
Residential, outpatient, and medication-assisted treatment programs serving individuals with alcohol, opioid, and substance use disorders.
- 5
- Verticals
Overview
Addiction & Substance Use Treatment covers residential, outpatient, and medication-assisted treatment (MAT) programs for alcohol, opioid, and substance-use disorders. Demand has been driven by the opioid and broader addiction crisis, and MAT (methadone, buprenorphine) has expanded access to evidence-based care.
Private equity has consolidated treatment providers (BayMark, Pinnacle, and others), but the sector has a fraught history of patient-brokering scandals, quality concerns, and reimbursement volatility, and that history shapes both regulation and reputational risk. Demand remains high and structural.
Market snapshot
No single discrete Census NAICS code covers addiction treatment, which spans outpatient centers (621420), residential (623220), and hospitals (622210), so the segment is not separately sized by the Census Bureau.
Business model & economics
Revenue model
Per-diem residential, outpatient, and MAT reimbursement
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 12–22%
- Capex intensity
- Moderate
recurring MAT and outpatient care
Characteristics
- Demand driven by the opioid and addiction crisis.
- MAT expanded evidence-based, recurring treatment.
- Fraught history of scandals and quality concerns.
M&A deal context
Who’s acquiring
- PE-backed treatment platforms
- MAT and outpatient consolidators
- Behavioral-health operators
What’s driving deals
- Consolidation of treatment providers.
- Opioid-crisis and addiction demand.
- Regulatory and reputational scrutiny.
Verticals in this segment
Find Addiction & Substance Use Treatment acquisition targets
Search Acquisera’s index for companies classified under Addiction & Substance Use Treatment (4.2.2) and build a targeted deal pipeline.
Search companies